The first civilian mission to the Moon is planned to take place in 2023. The rocket developed by Elon Musk’s SpaceX will make a week-long journey to the Moon and back. In 2018,Japanese entrepreneur Yusaku Maezawa purchased all the seats aboard this rocket.Wishing to give as many talented individuals as possible the opportunity to go,he announced in March 2021 his plans to choose 8 crew members from across the world.
A Japanese company that focuses on aerospace technologies. I love their rocket designs. I can’t wait to start producing spaceships of my own one day. I want to see humanity become completely self-sufficient in technology. It’s vital for the preservation of our species.
I believe the future of humanity is in space travel. Mars is the first step of an exciting future! Who knows where we might go next… Perhaps we’ll be going to distant solar systems in a few centuries.
dw2 – Delta Wisdom’s blog of discussions of the future
My initials were “DWW” when I was born into the world as David William Wood. I became infatuated with Lady Mathematics, my first true love, a few years later. I then adopted the algebraic term “dw2” as my nom de plume. My first online presence was in the UK on the CIX bulletin boards system in the early 1990s. There, I used the ID dw2. Welcome!
Over 25 years, I have been closely involved in enabling rapid growth of mobile device capabilities. I plan to devote the next 25 years to envisioning and enabling smarter human beings who radically surpass legacy limitations.
Lucy Therapeutics – Female-founded biotech company Lucy Therapeutics
We are filled with curiosity as we seek to identify what signals cause healthy cells to become disordered or dysfunctional. Mitochondria have caught our attention as potentially key drivers of complex conditions, particularly disorders of the central nervous and cardiovascular systems. We are investing tireless effort to unlock the complexities and explore the interrelated processes that lead to mitochondrial dysfunction. Our ultimate ambition lies in arresting diseases and finding a path back to health.
Regenerative Medicine Daily
Regenerative medicine is an exciting and rapidly-growing field of study. Life extension companies are turning to this discipline to develop new ways of helping people live longer and healthier lives. Regenerative Medicine Daily is an unique platform dedicated to bringing the world’s most cutting edge news and information on regenerative medicine. From developments in stem cells and gene therapy, as well as ground-breaking treatments for age-related diseases, the site unabashedly covers sensible applications for regenerative technology across multiple industries. With its laser focus on the science and results of regenerative medicine, Regenerative Medicine Daily serves readers around the globe who want real facts to help them understand innovation which promises great life improvements.
The Clock Foundation is making epigenetic aging clocks more accessible for use in preclinical and clinical studies.
The Epigenetic Clock Development Foundation (” Clock Foundation“), a UCLA spin-out non-profit, is working to speed up the availability of treatments that extend life expectancy and health. Our focus is on adaptive clinical trials and epigenetic aging clocks. We will develop and identify key enabling technologies, identify promising teams, and make them available for our partners including researchers, physicians/clinics and drug development companies.
The epigenetic aging clocks are powerful indicators of biological age. Their reversal promises to lower the risk for multiple chronic diseases as well as to maintain the immune system. Preclinical and human studies have shown that epigenetic clocks can be used as a surrogate endpoint in anti-aging clinical trials.
We want to lower the cost of epigenetic testing and to do mechanistic studies. In addition, we will develop more powerful biomarkers for predicting lifespan and health span (including a fast, safe, and effective testing program for humans, model organisms, companion animals, and other pets). We will test and analyze several biomarkers of ageing, including markers of immunosenescence and epigenetic aging clocks. The work will lead to the qualification of several biomarkers for aging as surrogate trial ends.
Through our partners and collaborators we are currently conducting proof-of-concept studies on aging. We plan to create efficient, large-scale preclinical/clinical trial infrastructure in the U.S. as well as internationally. Our team has extensive experience in healthcare and life sciences, as well as deep knowledge in clinical translation and basic research. This team includes members of the TRIIM trial research group, which was a recent study that showed the reversal in epigenetic aging and other key aspects of immunosenescence among healthy older men between 50-65.
Why Us? Why now?
The past ten years of research by Dr. Steve Horvath has led to a revolution in aging science. This was possible thanks to the collaboration of data from hundreds clinical studies and tens upon thousands of patients. This unprecedented level of data sharing and accessibility of digital data was not possible 15 years ago. Our team proved that human epigenetic ageing could be reversed by using a combination FDA-approved drugs. This groundbreaking study demonstrated the importance of a non-profit infrastructure to rigorously assess and develop promising anti-aging therapies. We believe that, despite the public’s interest in longevity medicine and venture capital investment at an early stage, there is a lack of clear regulatory guidance and incentives that are hindering its development. These challenges will continue to impede the development of effective, affordable and safe preventive medicine that targets the biology of aging.
The Impact and Our Massively Transformative Purpose
Our goal is to make it possible for everyone to escape the slow aging process using affordable and safe interventions. This is possible by making epigenetic clock technology more accessible and ensuring its consistent use in clinical and preclinical research. Partly, we will follow the FDA’s approach, which helps ensure that new treatments are safe and effective. However, we will also help to craft and establish their approach for approving preventive medicine by regulatory development work on epigenetic age clocks. Our foundation is focused on continuing to achieve remarkable clinical and preclinical trials results. However, we have a deeper, longer-term and more comprehensive approach. This includes acquiring an in-depth understanding of the biology and mechanisms of aging, particularly with the new powerful “lens”, epigenetic ageing and epigenetic clocks. This is an element we consider essential that forms the foundation of our goals.
My Aging Test
A website that provides information on aging and longevity research. The reversal of epigenetic aging clocks promises to lower the risk of multiple chronic diseases and preserve the immune system.
MyAgingTests.comis a community branch of the Clock Foundation. This non-profit, which is longevity-oriented, is based in Los Angeles.
The Epigenetic Clock Development Foundation (“Clock Foundation”), a UCLA spin-out, is working to speed up the availability of treatments that extend life expectancy and health. Our focus is on adaptive clinical trials and epigenetic aging clocks. We will develop and identify key enabling technologies, identify promising teams, and make them available for our partners including researchers, physicians/clinics and drug development companies.
The epigenetic aging clocks , which are strong indicators for biological age, can be reversed to reduce the risk of many chronic diseases and preserve the immune system. Preclinical and human studies have shown that epigenetic clocks can be used as a surrogate endpoint in anti-aging clinical trials.
Our goal is to lower the cost of epigenetic testing and to perform mechanistic studies. We also aim to develop more powerful biomarkers to predict healthspan and longevity (including a fast, safe, and effective testing regimen for humans, model organisms and companion animals). We will test and analyze several biomarkers that indicate aging, including markers of immunosenescence and epigenetic aging clocks. The work will lead to the qualification of several biomarkers for aging as surrogate trial ends.
According to a new study, just 1 minute of exercise a few times per day may help you live longer.
Engaging in short, vigorous activities every day may reduce your risk of dying from cancer or heart disease. A recent study published December 8 in Nature Medicine found that even brief bouts of vigorous activity are linked to health benefits. People who did vigorous activity 11 short sessions per day had a 65% lower risk of dying from cardiovascular disease, and 49% lower risk of dying from cancer, compared to those who didn’t do any vigorous activity.
Getting more movement in your daily routine may be a useful strategy for improving your health. A new study suggests that doses of exercise, even smaller than what is currently recommended, can bring about health benefits.
You are the visionaries behind the new products and transformative technologies shaping the future. It’s time to reach thousands of decision-makers with real buying power. Inspire the next generation, meet with industry bigwigs and set yourself up for serious success.
When you ask ChatGPT “Can a human live more than 200 years?”
Can a human live more than 200 years?
It is currently not possible for a human to live more than 200 years. The longest-lived person in recorded history was Jeanne Calment, who lived to the age of 122 years and 164 days. While it is theoretically possible that advances in medicine and technology could extend human lifespan, it is not known if it would be possible for a person to live beyond 200 years.
How AI is being used to develop anti-aging drugs
With the use and development of artificial intelligence (AI), the future of anti-aging is in a new era. Scientists are turning to machines that cannot experience age themselves.
How AI is changing the way we develop drugs Speed, accuracy, and precision are crucial in the field of drug development?
It takes a long time to develop a new drug and get it on the market. This is especially true for anti-aging treatments, which take a long time to show any results. The problem is that when a drug patent starts, it starts from the beginning of the pipeline, not when the drug is released to the public. If it takes more than 20 years to test a drug and see if it works, then we can’t make any money off of it.
Many companies are using AI to identify promising compounds for drugs. This can be done in several different ways.
- Researchers at Atomwise wanted to know if any existing, FDA-approved medications could be useful for fighting Ebola. They found a likely target for intervention- a particular point on a viral coat protein that needs another protein to operate. They hoped that by blocking the receptor they could prevent the virus from entering cells. After training their model by asking how well a set of compounds fit the target receptor, they fed the algorithm new compounds and asked how well these fit. Out of 7000 compounds, they identified 17 promising compounds.
- Numerate wanted to use a molecule that would fit the same receptor as ApoE4 to target Alzheimer’s disease. They used a process called scaffold hopping to generate molecular formulas for compounds that would fit the same receptor. This process took about 9 months and cost $1,000,000. Out of 10 million compounds, they found 10 that were patentable. 4 of those went on to pass in vivo studies.
- Some companies use computers to learn how poisonous a drug might be. The computer looks at how poisonous different drugs are and what they are made of. Then it guesses how poisonous a new drug might be. This helps the company save money because they don’t have to test every new drug to see if it is poisonous.
- BioAge Labs took a different approach to finding new drugs. They looked for biomarkers instead of using deep learning. Biomarkers are measurements that are highly predictive of aging outcomes. This allows you to evaluate the use of your intervention without waiting for the event you are trying to cause or avoid. For example, looking for treatments that reduce blood pressure is easier than looking for treatments that reduce heart attacks, because you’re able to get statistically significant results from a smaller sample size over a shorter period of time. This means that useless compounds are discarded sooner, and promising compounds are brought to the public faster.